Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.

[1]  E. Romanowski,et al.  Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. , 1994, Investigative ophthalmology & visual science.

[2]  W. Owen,et al.  Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. , 1994, The Journal of infectious diseases.

[3]  E. De Clercq,et al.  Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  W. Freeman,et al.  Long-acting therapy of viral retinitis with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine. , 1994, The Journal of infectious diseases.

[5]  E. Clercq.  Antivirals for the treatment of herpesvirus infections , 1993 .

[6]  L. Stanberry,et al.  Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs. , 1993, Antiviral research.

[7]  E. De Clercq,et al.  Pretreatment with Topical 0.1% (S)-1 -(3-hydroxy-2-phosphonylmethoxypropyl)cytosine Inhibits Adenovirus Type 5 Replication in the New Zealand Rabbit Ocular Model , 1992, Cornea.

[8]  R. Whitley,et al.  Effect of (S)-1-[(3-hydroxy-2-phosphonyl methoxy) propyl] cytosine on the replication and morphogenesis of herpes simplex virus type 1. , 1992, Antiviral research.

[9]  I. Votruba,et al.  Pretreatment of the host cell with 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) is sufficient for its antiviral effect. , 1992, Acta virologica.

[10]  E. De Clercq,et al.  Efficacy of (S)‐1‐(3‐hydroxy‐2‐phosphonylmethoxypropyl)cytosine and 9‐(1,3‐dihydroxy‐2‐propoxymethyl)guanine for the treatment of murine cytomegalovirus infection in severe combined immunodeficiency mice , 1992, Journal of medical virology.

[11]  E. De Clercq,et al.  Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine. , 1992, Investigative ophthalmology & visual science.

[12]  E. Romanowski,et al.  An ocular model of adenovirus type 5 infection in the NZ rabbit. , 1992, Investigative Ophthalmology and Visual Science.

[13]  R. Datema,et al.  Prolonged and potent therapeutic and prophylactic effects of (S)-1-[(3-hydroxy-2-phosphonylmethoxy)propyl]cytosine against herpes simplex virus type 2 infections in mice , 1991, Antimicrobial Agents and Chemotherapy.

[14]  E. De Clercq,et al.  Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. , 1991, Antiviral research.

[15]  E. De Clercq,et al.  Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. , 1991, Antiviral research.

[16]  E. De Clercq,et al.  (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine in the therapy of thymidine kinase-positive and -deficient herpes simplex virus experimental keratitis. , 1991, Investigative ophthalmology & visual science.

[17]  E. De Clercq,et al.  Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice , 1991, Antimicrobial Agents and Chemotherapy.

[18]  E. Romanowski,et al.  Replication of ocular isolates of human adenovirus is serotype-dependent in rabbit corneal organ culture. , 1991, Current eye research.

[19]  E. De Clercq,et al.  (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication , 1988, Antimicrobial Agents and Chemotherapy.

[20]  K. Nelson,et al.  Epidemiology of epidemic keratoconjunctivitis. , 1987, Epidemiologic reviews.

[21]  J. Beck,et al.  Enzyme immunoassays with special reference to ELISA techniques. , 1978, Journal of clinical pathology.